Turnstone Biologics Corp.
NASDAQ Global MarketTotal Valuation
Turnstone Biologics Corp. carries a market capitalization of 8.21M, placing it among publicly traded companies globally. Its enterprise value stands at -7.99M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 8.21M |
| Enterprise Value | -7.99M |
Share Statistics
Turnstone Biologics Corp. currently has 23.14M shares outstanding.
| Shares Outstanding | 23.14M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.03 |
| P/TBV Ratio | 0.56 |
| P/FCF Ratio | -0.18 |
| P/OCF Ratio | -0.18 |
Financial Position
Turnstone Biologics Corp. maintains a current ratio of 3.33, meaning it holds 3.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.33 |
| Quick Ratio | 2.63 |
| Debt / Equity | 2.78 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -96.34 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 33,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Turnstone Biologics Corp.'s stock has declined approximately -46.68869% over the past 52 weeks. The 50-day moving average sits at 0.36, while the 200-day moving average is 0.41.
| Beta (5Y) | N/A |
| 52-Week Price Change | -46.68869% |
| 50-Day Moving Average | 0.36 |
| 200-Day Moving Average | 0.41 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -43.34M, while operating income came in at -44.47M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -44.47M |
| Pretax Income | -47.17M |
| Net Income | -47.20M |
| EBITDA | -43.34M |
| EBIT | -44.47M |
| Earnings Per Share (EPS) | -2.04 |
Balance Sheet
Turnstone Biologics Corp. holds 16.69M in cash and equivalents against 411,000.00 in total debt, resulting in a net debt position of -16.69M. Total book value stands at -264.87M, with working capital of 14.76M providing operational flexibility.
| Cash & Cash Equivalents | 16.69M |
| Total Debt | 411,000.00 |
| Net Debt | -16.69M |
| Equity (Book Value) | -264.87M |
| Book Value Per Share | -11.47 |
| Working Capital | 14.76M |
Cash Flow
Turnstone Biologics Corp. produced -45.45M in operating cash flow over the past twelve months. After subtracting 20,000.00 in capital expenditures, free cash flow totaled -45.43M - equivalent to -1.97 per share.
| Operating Cash Flow | -45.45M |
| Capital Expenditures | 20,000.00 |
| Free Cash Flow | -45.43M |
| FCF Per Share | -1.97 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.71 |
| FCF Yield | -548.42 |
Scores
Turnstone Biologics Corp. posts an Altman Z-Score of -22.90, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -22.90 |